Subtitle: Market Intelligence for Metabolic Pathway Inhibition and High-Purity Reagents for Lysine/Kynurenine Metabolism Research
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AADAT (KAT II/KYAT2) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AADAT Recombinant Protein (Wild-type & PLP-binding Mutants) High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. Theoretical MW confirmed. |
View AADAT Products |
| Gene Delivery | AADAT Promise-ORF / Lentivirus Full-length ORF with mitochondrial targeting sequence (MTS) preserved for authentic subcellular localization. |
View AADAT Products |
| Benchmark Ab | Anti-AADAT (KAT II) Monoclonal Sequence-defined recombinant antibody for Western/ELISA validation. |
View AADAT Products |
| Validator | AADAT siRNA Set For specific knockdown validation in metabolic rescue studies. |
View AADAT Products |
| Paralog Control | KYAT1 (KAT I) Recombinant Protein For selectivity screening vs. kynurenine aminotransferase I. Sequence Verified. |
View KYAT1 Products |
| Pathway Partner | IDO1 Recombinant Protein Upstream kynurenine pathway regulator for combination studies. |
View IDO1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PLP Cofactor Binding Integrity | Sequence-verified active site lysine (K242) preserved; Purity >95% for consistent cofactor binding kinetics |
| Selectivity vs. KYAT1 (Paralog) | Human KYAT1 & AADAT ortholog proteins strictly verified by mass spec for paralog discrimination assays |
| Mitochondrial Localization Studies | Lentivirus with native MTS for authentic compartmentalization in metabolic flux analyses |
| Metabolic Flux False Positives | Validated siRNA included for specific knockdown confirmation; Rescue clones available |
Live AADAT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AADAT (KAT II) therapeutics is intensifying, with major players shifting focus from broad immunosuppression to precise metabolic modulation. As understanding of the kynurenine pathway's role in neurodegeneration and immuno-oncology deepens, first-generation small molecule inhibitors are entering Phase I trials. The next wave of R&D is targeting brain-penetrant selective inhibitors and PROTAC degraders for sustained pathway suppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Roche, Takeda, Pfizer | Major Depressive Disorder, Alzheimer's | Enzymatic Activity Assay (Need high-purity WT & mutant proteins with PLP binding capacity) |
| PROTACs | Arvinas, C4 Therapeutics | Oncology (Immune Evasion) | Cellular Degradation Assay (Need stable overexpression cell lines via Lentivirus) |
| Metabolic Modulators | BioNTech, Ideaya | Refractory Solid Tumors | Pathway Flux Analysis (Need selective KYAT1 vs AADAT discrimination panels) |